Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

Antonios Bayas; Jean Christophe Ouallet; Boris Kallmann; Raymond Hupperts; Ulrich Fulda; Kurt Marhardt

doi:10.1517/17425247.2015.1057567

Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

Antonios Bayas^*, Jean Christophe Ouallet, Boris Kallmann, Raymond Hupperts, Ulrich Fulda, Kurt Marhardt

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

28 Citations (Web of Science)

Abstract

Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score

Original language	English
Pages (from-to)	1239-1250
Journal	Expert Opinion on Drug Delivery
Volume	12
Issue number	8
DOIs	https://doi.org/10.1517/17425247.2015.1057567
Publication status	Published - Aug 2015

Keywords

adherence
autoinjector
interferon beta
multiple sclerosis

Access to Document

10.1517/17425247.2015.1057567

Cite this

Bayas, A., Ouallet, J. C., Kallmann, B., Hupperts, R., Fulda, U., & Marhardt, K. (2015). Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. Expert Opinion on Drug Delivery, 12(8), 1239-1250. https://doi.org/10.1517/17425247.2015.1057567

@article{8a4ad0d06f704ee2b61be55fde7528e7,

title = "Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study",

abstract = "Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score ",

keywords = "adherence, autoinjector, interferon beta, multiple sclerosis",

author = "Antonios Bayas and Ouallet, {Jean Christophe} and Boris Kallmann and Raymond Hupperts and Ulrich Fulda and Kurt Marhardt",

year = "2015",

month = aug,

doi = "10.1517/17425247.2015.1057567",

language = "English",

volume = "12",

pages = "1239--1250",

journal = "Expert Opinion on Drug Delivery",

issn = "1742-5247",

publisher = "Informa Healthcare",

number = "8",

}

Bayas, A, Ouallet, JC, Kallmann, B, Hupperts, R, Fulda, U & Marhardt, K 2015, 'Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study', Expert Opinion on Drug Delivery, vol. 12, no. 8, pp. 1239-1250. https://doi.org/10.1517/17425247.2015.1057567

Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study. / Bayas, Antonios; Ouallet, Jean Christophe; Kallmann, Boris et al.

In: Expert Opinion on Drug Delivery, Vol. 12, No. 8, 08.2015, p. 1239-1250.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Adherence to, and effectiveness of, subcutaneous interferon beta-1a administered by RebiSmart (R) in patients with relapsing multiple sclerosis: results of the 1-year, observational SMART study

AU - Bayas, Antonios

AU - Ouallet, Jean Christophe

AU - Kallmann, Boris

AU - Hupperts, Raymond

AU - Fulda, Ulrich

AU - Marhardt, Kurt

PY - 2015/8

Y1 - 2015/8

N2 - Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score

AB - Background: Patients with multiple sclerosis who have poor adherence to treatment have a higher risk of relapse than adherent patients. This study assessed adherence to, and effectiveness and convenience of, treatment with subcutaneous (sc) interferon (IFN) beta-1a (Rebif, Merck Serono SA) 44 or 22 mu g three times weekly in patients with relapsing multiple sclerosis (RMS) using the RebiSmart (R) electronic, multidose, autoinjector for 1 year. Study design: European, multicentre, observational study among neurologists: inclusion criteria included RMS, Expanded Disability Status Scale score

KW - adherence

KW - autoinjector

KW - interferon beta

KW - multiple sclerosis

U2 - 10.1517/17425247.2015.1057567

DO - 10.1517/17425247.2015.1057567

M3 - Article

C2 - 26098143

VL - 12

SP - 1239

EP - 1250

JO - Expert Opinion on Drug Delivery

JF - Expert Opinion on Drug Delivery

SN - 1742-5247

IS - 8

ER -